Corvus Pharma rallies 40% on promising CPI-006 data in COVID-19

• Corvus Pharmaceuticals (NASDAQ:CRVS) announces encouraging data from its ongoing Phase 1 study investigating CPI-006 in COVID-19 patients.
• Updated data include 56-day follow-up results from the first two cohorts (0.3 mg/kg and 1.0mg/kg dose) and initial results from the third cohort (3.0 mg/kg) of the study.
• Day 56 results showed a dose-response, with higher and more prolonged titers of anti-SARS-CoV-2 antibodies in the 1.0 mg/kg cohort compared to the 0.3 mg/kg cohort.
• In addition, the results showed increased levels of memory B cells and memory T cells, and there have been no reports of any drug-related safety issues in any of the 15 patients treated as of September 17.
• As of September 28, 14 of 15 patients were discharged from the hospital with clinical improvement after a median of 4.5 days. One patient remains in the hospital with improvement of symptoms.
• Corvus expects to complete the study and report results this quarter, including a presentation at the Society for Immunotherapy of Cancer (SITC) meeting next month.
• A double blind study in hospitalized COVID-19 patients is next up.
• https://seekingalpha.com/news/3619747-corvus-pharma-rallies-40-on-promising-cpiminus-006-data-in-covidminus-19